Thanks for explanation, EP. eom.

Hi EP....for the TA challenged...could you 'say' that in English? Thanks.

Are you back in BIPH? I'm gradually increasing a position for a long term hold in UGNE.

Biophan Announces Appointment of Former Genencor Executive Darryl L. Canfield to Post of Chief Financial Officer
Monday December 19, 10:00 am ET
Current CFO Robert J. Wood to Move to Consulting Capacity in January


ROCHESTER, N.Y.--(BUSINESS WIRE)--Dec. 19, 2005--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, announced today the retirement of Robert J. Wood, age 66, Chief Financial Officer, Vice-President, Treasurer, and Secretary, effective January 20, 2006. Mr. Wood will be succeeded in those positions by veteran biotechnology industry executive Darryl L. Canfield, whose 30-year career includes key financial positions at firms such as biotechnology development leader Genencor International.



Following his resignation from Biophan, Mr. Wood will continue to serve the Company for a period of time as a financial consultant for special projects and corporate support. "Bob Wood has served as CFO since August 2001, and has been a key player in Biophan's corporate development and strategic planning," said Michael Weiner, Biophan's CEO. "He has served with dedication and excellence and we thank him for his many contributions."

On the effective date of Mr. Wood's resignation, he will be succeeded by Mr. Canfield, age 59. For the past five years Mr. Canfield has been employed as Vice President, Corporate Controller, and Chief Accounting Officer at Genencor International, Inc. a $400 million, internationally recognized leader in the development and manufacture of innovative diversified products for the biotechnology industry. Genencor was a NASDAQ-listed company until it was sold in April of 2005. He is a New York State Certified Public Accountant and is a member of the American Institute of Certified Public Accountants, the New York State Society of Certified Public Accountants, and Financial Executives International, and has extensive experience working with the requirements of the Sarbanes-Oxley Act.

"I am very pleased to announce that Darryl Canfield is joining Biophan and we believe his experience will prove to be a valuable asset to our company as we progress to the next stage of growth," Mr. Weiner said. "We look forward to his counsel and guidance."

Mr. Canfield said, "I am excited to take on the opportunity offered by Biophan as the Company continues into the next phases of technology and business development, and further executes its mission to deliver visionary medical technology to the medical device industry."

http://biz.yahoo.com/bw/051219/20051219005257.html?.v=1

From the National Heart, Lung, and Blood Institute info below, the time is ripe for the Myo-vad, but a search of the NHLBI site found no reference of Myo-Vad, Myotech or Biophan (there's also some initiatives to use nanotechnology in heart/lung/blood disease).

Does anyone recall if MW has ever referenced contact with NHLBI?

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
STRATEGIC PLAN
FY 2005-2009
Action:

Potential FY 2005 initiative:
Develop the next generation of ventricular assist devices to be used as permanent, mechanical therapy for patients with advanced heart failure. Heart failure, which affects about 5 million Americans, develops over time as the heart loses its ability to pump blood through the body. Each year, between 50,000 and 100,000 patients experience such advanced heart failure that they qualify for heart transplantation. However, because the heart donor pool is less than 2,500 per year, alternative therapies are needed. Currently, a ventricular assist device (VAD), which is a mechanical pump that helps the heart pump blood through the body, can be used to support patients with failing hearts until a donor heart becomes available. Recently, the NHLBI-supported REMATCH trial demonstrated that ventricular assist devices (VADs) could be used to treat critically ill heart failure patients, with better survival and quality of life than can be expected from optimal medical therapy. However, patients with VADs still faced the risk of serious complications such as bleeding, blood clots, infection, device malfunction, and device failure. Research is needed to expand the capabilities, utility, and efficiency of VADs through improved design and other device enhancements. A program is needed to develop VAD designs that reduce VAD-related infections, improve VAD biocompatibility, develop new VAD energy sources, and optimize VAD function and reliability.


http://www.nhlbi.nih.gov/resources/docs/plan/treat.htm

also:
http://www.nhlbi.nih.gov/meetings/workshops/nextgen-vads.htm

Oops....Howard Greenwald is one of BIPH's "Patent and Intellectual Property Counsel". One thing led to another, and awhile ago I landed on this site

http://www.greenwaldpc.com/index.htm.

Click on "our Capabilities" and then "Issued Patents". On the right side of the list go to "Biomedical Devices" and click the first one, 'Apparatus for Assisting a Heart'. No matter how many times I try, I get a patent for a Pet Training Device. Now try 'Biothermal Power Source..'... and guess what comes up? Printer Cassette!!

Go ahead...try another, how about on the lower left "Construction" area....go to 'Interlocking Building Block' and see that the referenced patent is for Water Treatment Process.

"Our Capabilities" for Greenwald's site has flunked miserably. But I'm sure they're doing just fine for BIPH. :(

(Wonder how long before the message gets to the site to correct the links to patents. Wonder who the messenger will be and will the message go Uphill?)

The presentation is over but the mic is still on and you can hear MW in the background chatting with attendees. Haven't picked up anything earth shattering, though!

Some of MW's best stuff is in the Q&A session going on now.

You can listen to today's presentation here:
http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp#

If you're quick, you can get a question submitted...see link near top of page. MW presents at 11:25.

OT, sort of: This is an older article, and I realize it's the NYSE not the AMEX, but it's interesting to note the bolded portion below:

http://www.studyfinance.com/jfsd/pdffiles/v7n1/iqbal.pdf

Listing Procedure On The NYSE
In order to obtain a listing on the NYSE, a firm must meet certain standards that include a minimum number of
shares held by the public, a minimum market value for shares outstanding, a minimum pre-tax income, a
minimum net tangible asset size etc. Before filing a formal application with the exchange, virtually all firms seek
a confidential preliminary opinion from the exchange. This insures that the firm will be approved for listing once
a formal application is filed. The application for listing is officially reported in the NYSE Weekly Bulletin,
published on the first Friday following the day of formal application. Thus, investors become aware of a firm's
intention to get listed during the application week. Approximately four weeks after the formal application is filed,
the exchange renders a decision which is reported in the following Friday's Weekly Bulletin. The firm must also
register with the Securities and Exchange Commission (SEC) before actual listing takes place. The typical time
lag from formal application to listing is roughly two months.

In an interview dated Aug 19, '05, MW said the following:

"...As a result of this deal, we meet the qualifications for listing on a major exchange and we are now in the middle of that process."
http://www.wallstreetreporter.com/linked/BiophanTechnologiesInc.html

So here we are nearly four months down the road...where's the beef? Does anyone have experience with another company and how long the application approval process for AMEX took?

I'm not really expecting huge movement in SP with a listing...I'm more interested in seeing a confirmation of MW's word.

From another board...

By: nimble-toes
06 Dec 2005, 10:01 AM EST
Msg. 7428 of 7428
Jump to msg. #
Last night, after the closing bell, BI Research, a stock newsletter that has been consistently rated in the top five by Hulbert, made Unigene its new stock pick. BI's stamp of approval is a nice step for Unigene. It's the first BB stock that I can remember BI picking. I think this is the driving force behind today's action.

There were a few sessions such as this at the RSNS meeting which BIPH is attending as an exhibitor. (There's over 700 exhibitors.) Interesting...

http://rsna2005.rsna.org/rsna2005/v2005/conference/event_display.cfm?id=66601&p_navID=272&em...

SESSION: Minicourse: Optimize Your Body MR Practice—From Safety to Protocol Design: MR Imaging Safety for Implants and Devices
Pacemakers, Implantable Cardioverter Defibrillators, Retained Leads, and Related Issues




Presenter
James Coman MD

DATE: Sunday, November 27 2005
START TIME: 02:00 PM
END TIME: 03:30 PM
LOCATION: N228

LEARNING OBJECTIVES
1. Recognize the theoretical risks of MRI and MRA scanning in patients with permanent pacemakers and ICDs. 2. Understand strategies for minimizing patient, as well as device risk, during MRI scanning. 3. Examine the available data on adverse outcomes for patients with permanent pacing devices and MR scans.

ABSTRACT
Since the inception of MR scanning techniques, patients with permanently placed pacemakers and defibrillators have been denied access to this increasingly valuable diagnostic tool. The fears over adverse interactions between permanently placed pacing generators and MR machines have been largely based on theory and phantom model testing. Documented negative consequences in human patients has been surprisingly lacking. Over the past 8 years, numerous patients with implanted devices have experienced purposeful MRI and MRA scans. The largest of these studies was conducted without any restrictions on the type of imaging and with minimal reprogramming of the implanted devices. The study, conducted at the Oklahoma Heart Institute, revealed rare rises in the pacing thresholds of leads and occasional oversensing difficulties. None of the pacemakers or lead-tissue interfaces were permanently damaged. On the other hand, at least 2 implantable defibrillators have been permanently disabled as a consequence of scanning. No adverse patient outcomes have been noted. Overall, MRI and MRA imaging of non-dependant pacemaker and ICD patients can clearly be performed with an acceptable safety profile when appropriate monitoring is performed.

Thanks to 'drugdok' on the RB board where I pilfered this post.


By: drugdok
21 Nov 2005, 11:05 PM EST
Msg. 7273 of 7273
Jump to msg. #
DD on UGNE.ob

1. ONLY biotech company to both manufacture and deliver peptides.
2. Has approval for competitor to Miacalcin (norvartis drug) for osteoporosis ($236 mm/year)...branded FORTICAL.
a. Makes calcitonin so pure and cheap that NVS licenced
manufacturing technology to implement in own drugs.
1. UGNE to reap benefits in royalty from any
product made with their calcitonin manufacturing
2. Able to buy all calcitonin it needs from NVS at
pre-negotiated price.
3. Fortical is being heavily promoted by UGNE partner Upsher-Smith laboratories ( a billion dollar drug company), while miacalcin apparently has not been promoted by NVS.
4. NEW indications for calcitonin nasal sprays might be approved in the near future...possibly for osteoarthritis, a condition 20mm people have in the USA.
5. Fortical is not only much cheaper to make than miacalcin,
but also doesn't have the known nasal irritant
benzalkonium chloride, which is irritating to the nasal
mucous membranes.
**UGNE has filed an ANDA in China for Fortical on
09/04/03, and has a partner ready to launch once
approval is granted. China is by far the biggest
osteoporosis market on earth.
6. NVS has implemented UGNE process (at a tenfold scale
and is in the process of launching sometime in the near
future, a phase III for oral calcitonin, a drug which has blockbuster potential, giving UGNE royalties indefinitely.
7. According to CEO, UGNE has own oral calcitonin program,
which they have already completed 7 human studies
with...and they are apparently in discussions with
Anxious partners currently.
8. UGNE also has a worldwide deal (worth > $150mm) with GSK
for an oral PTH drug. GSK is reportedly agressively
planning phase II study. Only $5/150mm been received
so far.
a. PTH has potential to grow bone.
b. Calcitonin stops bone from degenerating.
1. Drugs could someday be complementary combo.
9. Recently announced they have made inventions which could
someday grow bone in an outpatient setting.
a. Improve healing process in fractures.

10. UGNE has potential to manufacture/deliver ORALLY...

a. DDAVP
b. INSULIN
c. Lupron

**ALWAYS DO YOUR OWN DD BEFORE BUYING OR SELLING ANY STOCK**

10Q 11/21/05


http://www.unigene.com/investor_relations/financials.html

OT: Avian Flu...this article is insurance company related, but the numbers are really staggering.
-------------------------
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh68193_2005-11-10_21-30-09_n07...

Avian flu may cost US 1 mln lives, $200 bln-study
Thu Nov 10, 2005 04:30 PM ET
By Ed Leefeldt
NEW YORK, Nov 10 (Reuters) - If a virulent strain of avian flu got loose in the United States, it could result in more than a million deaths and cost upward of $200 billion, according to a soon-to-be-released study by a leading U.S. insurance industry group.

"It would be like having a hundred separate Hurricane Katrinas in a hundred different places," said Stephen Weisbart, author of the study by the New York-based Insurance Information Institute (III), referring to this summer's disastrous hurricane.




SERIOUS THREAT

Avian flu cases have so far been limited to those who had direct exposure to infected chickens but world leaders are taking the threat that it will mutate into a human-transmitted strain seriously.

President Bush has asked Congress for $7 billion to combat a potential pandemic, an epidemic that moves from country to country at whirlwind speed.

If the flu became widespread, the federal and state governments would be overwhelmed and able to play only a limited role, Weisbart said.

"They'd all be too busy trying to save themselves," said the researcher.

Weisbart's report on the possible effects of avian flu is perhaps not a worst-case analysis. He goes back to the pandemic of 1918, when 675,0000 Americans died from influenza.

"If you project that to today's population, 1.7 million would die," he said. Current U.S. population is nearing 300 million.

Only 2.5 percent of those who got the flu then died. By contrast, nearly 50 percent of those exposed to the current avian flu have expired.

The most recent pandemic, the 1957 flu, killed nearly 100,000 people in the United States.

Equally important is who dies, said Weisbart. While normal flu kills the very young and old, the 1918 strain eliminated those in the 25-35 age bracket, prime years for holding life insurance.

The current outbreak of influenza, formally called H5N1 after two distinctive proteins on the flu virus, has so far affected Thailand, Vietnam, Indonesia and Cambodia.

Those countries have reported 120 human cases of the H5N1 flu since 1997. Sixty people have died, most after being sick for a few weeks.

This is a good overview of UGNE, products and potential presented at a Rodman and Renshaw conference:


http://www.wsw.com/webcast/rrshq7/ugne/

Biophan Completes Phase II and III of Development Agreement with Boston Scientific
Friday November 4, 4:01 pm ET
Company Recognizes Current Quarter Revenues


ROCHESTER, N.Y.--(BUSINESS WIRE)--Nov. 4, 2005--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, today reported the completion of phase II and phase III of its development agreement with Boston Scientific. The satisfactory completion of these milestones allows the Company to recognize $225,000 of previously received development payments as current quarter revenues.

Biophan is expected to receive additional revenue from Boston Scientific in January 2006 as a result of the recently executed license agreement between the two companies. Under the terms of the license agreement, Biophan anticipates an additional payment of $250,000 from Boston Scientific after January 1, 2006.

Michael Weiner, Chief Executive Officer of Biophan Technologies, said, "The completion of the first two phases of our development agreement with Boston Scientific represents a substantial milestone for Biophan. It demonstrates the growing validation of our technology by the biomedical device industry and the building momentum of its adoption. We are pleased to have achieved this first endorsement of our technology by a proven leader in the industry."

Biophan currently holds 156 U.S. patents, licenses or applications in its intellectual property portfolio, 42 of which have issued, plus 45 international applications. "We are progressing in discussions with a number of biomedical product manufacturers to license additional elements of our intellectual property portfolio," said Mr. Weiner. "These manufacturers are assessing Biophan's proprietary technologies to enable them to incorporate MRI safety and competitive performance advantages into their devices, including pacemakers, stents, neurostimulators, and others."

Sheesh....everybody makes money in hindsight. Just ask Ams.

I agree , EP, IHub is superior and more user friendly. The paid membership gets you all the goodies, but I think even as a free member IHub is better than RB. People considering IHub membership should try Happy Hour...here's is from IHub FAQ:
-----------------

What is Happy Hour? What are the times for it?


Happy Hour is blocks of time where all members have the premium features enabled. The whole enchilada (no ads, private messages, batch message viewing, everything!). It gives you the opportunity to see just how valuable the premium subscription is. Try it out! The times for Happy Hour are: Friday, 3-5pm EST.

I hear ya....but at this point I'm adding shares of UGNE and not more BIPH. I'm still averaged in on BIPH below a dollar, but I hate this downdraft and watching the ole portfolio take a hit. MW needs some new, substantial news for BIPH shareholders.

Hey, EP...I look forward to the day you start calling this on the way back up!

Thanks, EP, you're often right about these moves. eom.

I know you guys/gals trade here, but is anyone in UGNE for a long-term hold? (I've just started reading SEC and doing some other DD.) What's the plan for it to move to another exchange?

Thanks, EP, for your comments. Perhaps some new light will be shed in this call:

ROCHESTER, N.Y.--(BUSINESS WIRE)--Oct. 19, 2005--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, will host an investor conference call on Monday, October 24, at 10 a.m. Eastern, to provide a progress report on business and product development and commercialization of its intellectual property portfolio.

Senior Biophan officers including CEO Michael Weiner will discuss the strategic initiatives within the Company's Business Development Group, which was formed in August to accelerate the generation of revenues through Biophan's intellectual property portfolio and to develop technology-based products for important healthcare market segments.

"Biophan's business strategy is based on the commercialization of our broad intellectual property portfolio," said Mr. Weiner. "Toward that end we recently formed the Biophan Business Development Group to accelerate and expand our activities to license our extensive IP portfolio to leading biomedical product manufacturers. Monday's conference call will enable us to provide the maximum amount of information to investors and other interested parties about our progress in commercializing our intellectual property and product portfolio."

Biophan is a biomedical development leader with a powerful intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications. These patents include technologies to enable a variety of products and solutions within various multi-billion-dollar segments of the biomedical marketplace, including Magnetic Resonance Imaging (MRI) safety and image compatibility, and advanced drug-delivery and drug-elution technologies. Among the Company's recent product initiatives is a measure to expand its presence in cardiovascular diagnostic and therapeutic devices, one of the fastest-growing segments of the biomedical industry, with an expected value of nearly $28 billion before the end of this decade.

To connect to the conference call in the United States, please dial (800) 288-8967. International callers can dial (612) 332-0725. When prompted, please tell the operator that you would like to connect to the "Biophan Teleconference" call. This call is free of charge to all interested investors.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.



--------------------------------------------------------------------------------
Contact:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
OR
Press Interviews:
Jennifer Gould, 212-843-8037

EP: So, say you guys get your 1.50 or 1.87....where on the upside does it go from there? I added today.

Intellectual property drives business value


By FRANK SZIVOS

http://www.fairfieldcbj.com/current_issue/101705frop06.html

You often can't see it or touch it, but intellectual property (IP) might be a company's most valuable asset. Within the last 25 years, IPs (patents, trademarks and copyrights) have emerged as the primary driver of corporate assets.

The Association for Corporate Growth-Connecticut (ACG-CT) and Licensing Executive Society (LES), co-hosted a recent forum at the Millbrook Club in Greenwich, focusing the power of intellectual property in private equity deals. ACG-CT is a global association of professionals involved in corporate growth, development and mergers and acquisitions, while LES is a professional society for professionals engaged in development, manufacture, use and marketing of IP.

Guest panelist James Malackowski, president and chief executive officer of Ocean Tomo, an intellectual capital bank specializing in IP investment issues, said the time is ripe for early stage companies to profit from the importance of IP assets.

"For the U.S. economy, the shift from manufacturing to service is all but complete," Malackowski said. "We have now entered a new phase of economic development where value is captured through IP. Emerging business must have a thorough understanding and recognition of IP as a leading-asset class responsible for significant business growth."

Malackowski pointed out that investors are attracted to companies with IP assets. Research done by Ocean Tomo based in Chicago, has shown that investments in companies with strong intellectual property have a significantly greater chance of raising additional capital and offer half the risk of default. He predicted that investors will eventually hold portfolios of IP assets, similar to having a portfolio of stocks and bonds.

Panel member Emmett Murtha, president, Fairfield Resources International, services clients interested in developing and leveraging intellectual assets. The former director of licensing at IBM, noted that many companies sell off licensing rights to generate significant income. For example, IBM researchers perfected a laser eye surgery technique that it sold for $15 million.

"IBM was able to realize a nice piece of change," Murtha said. "And the company that purchased the IP rights did it so no one could compete and control the market."

Despite IBM's success, many companies have little or no clue about IP assets, often undervaluing or mismanaging them, Murtha said. Consider that:

+ Fewer than 3 percent of patents generate royalty income.

+ The Harvard Business Review reported that more than $1 trillion annually is wasted in patent assets. Failing to harness the power of IP is equally as negligent as failing to assign value to a company's IP portfolio.

+ Ernst & Young reports that patent licensing alone should soar from the $110 billion it generated in revenue in 2000 to $500 billion by 2015.

+ Qualcomm has generated as much as $430 million in licensing revenue in recent quarters while IBM has consistently brought in between $1.5 billion and $2.0 billion annually in licensing royalties.

Of course, mismanaging IPs presents other potential pitfalls. Companies that are negligent about IP rights can face a loss of patents, allegations of patent infringement and reserving enormous sums of money. There are plenty of examples of such problems. For instance:

+ Pfizer lost its patent for Viagra in China.

+ Brody Berman Associates estimates that the average cost of patent litigation is $2.5 million.

+ Research in Motion has reserved $100 million in view of its ongoing litigation

Robert D'Loren, president and CEO of UCC Capital Corp. and another panel member, noted that in the 21st century companies must realize that the power of the Internet that empowers consumers and the emergence of a world economy has dramatically changed the complexion of company assets and increased the value of IP.

"Remember that two years ago, 90 percent of home furnishings were produced here. Now, 90 percent of home furnishings are produced in China," D'Loren said. "The picture has changed incredibly. This is why intellectual property is so important." s

What is Adware Virtumundo... My McAfee scan calls it a "potentially unwanted program". I have Ad-aware and it's scan didn't pick it up, and Spybot didn't pick it up. Help appreciated...thanks in advance.

If some of you smarties (meant in only the nicest way) are having a slow evening, here's one: this is bugging me....I'm on MSN dial-up, and the service works fine.

But, when I sign off/disconnect the internet connection, the sign in screen doesn't become the small icon on the desk top. Noooooo, it pops up (two times) as if I'm going to sign in again. Only after clicking the "X" the two times, does it stay put on the desktop as a good little icon. How can I make it understand when I sign out, I mean it?

Is it hard of hearing? Or do I need to inflict some punishment?

OT: my3sons87....

Guess I know where I stand on being read on the IDCC board! Guess it's best to just lurk... lol :)

Posted by: ciciagt
In reply to: None Date:7/6/2005 10:35:16 AM
Post #of 126343

When the shoe is on the other foot, so to speak, look at Nokia's philosophy of getting paid....Please note this is from 2004, and in Jan of '05 they settled their dispute.

Nokia accuses Sagem, Vitelcom of patent infringement

04/11/2004 by Leigh Phillips

Finnish mobile handset manufacturer has launched legal proceedings against minor handset makers Vitelcom and Sagem, the company announced today, accusing the companies of patent infringement.

These are European complaints involving Nokia patents covering GSM and GPRS technologies. Nokia seeks injunctions against the continued sale and marketing of Spain-based Vitelcom's mobile phone products covered by the patents in the suit or monetary damages.

"Nokia has invested considerable time, energy and resources in its own research and development," said Ilkka Rahnasto, vice president, IPR, Nokia. "Vitelcom should play by the rules and licence needed intellectual property…We believe Vitelcom is using Nokia patented technologies without authority from or compensation to Nokia."

At the same time, the Finnish mobile giant is demanding France-based Sagem remove its MyX5-2 handset from the market, which it claims is a copy of one of its own designs and pay damages for the alleged

I see NaturalNano and Oncovista will both attend this Valuerich conference. (along with BIPH)

http://www.valuerichonline.com/ny05/index.php?id=nypresent

I'd sure like to see BIPH shareholders get a piece of the action on both of those.

http://www.oncovista.com/start_content.html

http://www.naturalnano.com/

OT plumear: That's a terrific post. Good luck and good wishes to you and your family that were affected by this storm and its aftermath.

We already have curtailed the "needless" driving in our cars and hope others can do so, too.

firerocket: Do you actually own shares of IDCC?

Check out the invited speakers for the conference MW is invited to later in August. MW stands out as a representative of a company, not a university like all the other speakers. He certainly seems to be held in high regard with his knowledge and accomplishments.

http://physics.bu.edu/icamnano/

Invited Speakers:

Ian Affleck, UBC
Ray Ashoori, MIT
Leon Balents, UC Santa Barbara
Gordon Baym, Illinois *
Ahmed Busnaina, Northeastern
Alexander Chernyshev, UC Irvine
Mike Crommie, UC Berkeley*
Kamil Ekinci, BU
David Goldhaber-Gordon, Stanford
Bert Halperin, Harvard
Joe Imry, Weizmann
Krzysztof Kempa, Boston College
Charles Marcus, Harvard
Carlo Montemagno, UCLA
Chetan Nayak, UCLA *
Franco Nori, Michigan and RIKEN
Masaki Oshikawa, Tokyo Inst. of Tech. *
Jeevak Parpia, Cornell
Dale Van Harlingen, Illinois
Michael Weiner, Biophan Technologies, Inc.
Ali Yazdani, Princeton

Interesting link from Forbes.....

Perot Backs $200 Million Bet On Patents
Tomas Kellner, 08.09.05, 6:00 AM ET

NEW YORK - Billionaire Ross Perot is the principal investor in a $200 million private equity fund set up to buy companies with undervalued patent portfolios--the first time that a private equity fund has been established solely to invest in intellectual property.

The fund, being set up by the Chicago merchant bank ICMB Ocean Tomo, is called Ocean Tomo Capital Fund, and will be acquiring or securing controlling stakes in patent-rich companies with revenue between $50 million and $1 billion. Areas of interests include semiconductors, biotech, nanotechnology and software.

Patents have recently become hot property. Just in the last two years, a number of small companies armed with patents but little or no product scored big patent-infringement victories against large businesses.

In April, the medical-device manufacturer Medtronic (nyse: MDT - news - people ) settled for $1.35 billion charges that it infringed on spinal-infusion technology patented by California surgeon Gary Michelson. In March, Canada's Research In Motion (nasdaq: RIMM - news - people ) settled a patent-infringement case related to its popular BlackBerry device for $450 million with NTP, a small Arlington, Va.-based outfit. In 2003, a federal jury in Chicago awarded tiny Eolas Technologies $521 million in damages for software patent violation by Microsoft (nasdaq: MSFT - news - people ).

The practice of acquiring intellectual property for profit, also called patent trolling, has been around for some time. However, this is the first time that a prominent investor would throw so much money in the game.

Another player betting on patents is former Microsoft Chief Technology Officer Nathan Myhrvold. His company, Seattle-based Intellectual Ventures, behaves more like a patent factory, however, employing inventors and patent lawyers to develop and patent valuable new ideas.

Perot, the maverick two-time presidential candidate, has a history of betting on promising technology.

He made the bulk of his $3.7 billion fortune by starting the data-processing company Electronic Data Systems (nyse: EDS - news - people ) and selling it for $1.4 billion in cash and stock to General Motors (nyse: GM - news - people ) in 1984. In the late 1980s, he paid $20 million for a 12% stake in a computer business called NeXT, which Steve Jobs started after leaving Apple Computer (nasdaq: AAPL - news - people ). Though NeXT was a dud, Apple acquired the company for $400 million in 1996, making Perot's stake worth $48 million.

http://www.forbes.com/services/2005/08/09/perot-patents-fund-cz_tk_0809patents.html?partner=yahootix

OT The Death of a Nokia Phone....

It had been a normal day so far: work, an evening walk, a stop at Starbuck’s.

But the day took on new life when I reached for the sprinkler timer and I saw it........an old Nokia cell phone. It was supposed to be kept for ‘demolition’ day with a friend’s children. (A couple months ago we dissected two old Pentium computers to see what was ‘inside’.)

Previously, I had guilt feelings about saving the old phone for demolition day because a local domestic violence shelter recycles phones for their clients. You know, Nokia could have done something useful. But, quite some time ago, I sent the shelter a nice check in lieu of the phone.

So now....here it was, just staring at me. N---O---K---I---A.

It might as well have said ‘Crush Me’, because very near to the right of this unsightly, black plastic glob was a shiny new hammer just looking for something to do. I wasted no time.

Hee, hee , hee.....I was feeling pretty good just imagining the feel of that hammer, poised to strike right in the heart of the phone. But first, I carefully wrote ‘IDCC’ and taped it to the hammer. Next, I set the enemy on the concrete floor of the garage, held the newly baptized hammer tightly in my hand.....and....WHAM! Black plastic went flying, the view screen splintered, and the last time I saw the number 3 it was scooting under the workbench. Ahh....that felt rreeeeeeeeeeeal good.

One Nokia phone down.....not that many to go in the USA.

Thanks for the news b9 and 'hawk...onward and upward!

renmanazO on RB has posted a great summary of his meetings with various key personnel at BIPH. Renman...hope you don't mind that I linked your post over here to IHub. (If I didn't link it correctly, it's worth the trip over to RB to read his post.) Thanks very much for your lengthy, helpful review.


http://ragingbull.lycos.com/mboard/boards.cgi?board=BIPH&read=66147

Thanks, 'hawk. eom.

Hi 'hawk...wow, BIPH possibly your best investment in over 30 years of being an individual investor. So, if you don't mind my asking...what would be your next best investment? I'd sure love to hear you say something like Microsoft!

Those are great photos tech has posted on the msn site. Thanks to all who attended for sharing their notes/thoughts on the meeting. Now we wait for the good ship Biophan to come in!

http://groups.msn.com/TheBiophanAttic/shoebox.msnw?Page=1